GAITHERSBURG, Md., July 26 /PRNewswire-FirstCall/ -- GenVec, Inc. (Nasdaq: GNVC) announced that research regarding GenVec's efforts to create novel vectors for vaccines is appearing in Vol. 28, issue 35, pages 5691-5702 of Vaccine. The article, "Potent immune responses and in vitro pro-inflammatory cytokine suppression by a novel adenovirus vector based on rare human serotype 28," describes GenVec's efforts to identify and utilize novel adenovirus serotypes as vectors in vaccine development.

"Identifying new adenoviruses capable of generating potent immune responses contributes to GenVec's leadership in vectored vaccine development," noted Douglas E. Brough, Ph.D., GenVec's Vice President of Research. "These new vectors could have major advantages for vaccines where it is critical to achieve potent stimulation of the immune system."  

About GenVec

GenVec, Inc. is a biopharmaceutical company developing novel therapeutic drugs and vaccines. GenVec uses its proprietary adenovector technology to develop TNFerade for the treatment of certain cancers and vaccines for infectious diseases including influenza, HIV, malaria, foot-and-mouth disease, respiratory syncytial virus (RSV), and HSV-2. GenVec also discovers and develops novel treatments for hearing loss and balance disorders through a worldwide collaboration with Novartis. Additional information about GenVec is available at www.genvec.com and in the Company's various filings with the Securities and Exchange Commission.

Statements herein relating to future financial or business performance, conditions or strategies and other financial and business matters, including expectations regarding future revenues and operating expenses, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act.  GenVec cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time.  Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the failure by GenVec to secure and maintain relationships with collaborators; risks relating to certain of our product candidates being in early stages of development; uncertainties relating to clinical trials; risks relating to the commercialization, if any, of GenVec's proposed product candidates; dependence on the efforts of third parties; dependence on intellectual property; and risks that we may lack the financial resources and access to capital to fund our operations.  Further information on the factors and risks that could affect GenVec's business, financial conditions and results of operations, are contained in GenVec's filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov.  These forward-looking statements speak only as of the date of this press release, and GenVec assumes no duty to update forward-looking statements.

SOURCE GenVec, Inc.

Back to top

RELATED LINKS
http://www.genvec.com